Pregnancy: There are no data for the use of PRAXBIND in pregnant women. Reproductive and developmental toxicity studies have not been performed, given the nature and the intended clinical use of the medicinal product. PRAXBIND may be used during pregnancy, if the expected clinical benefit outweighs the potential risks.
Lactation: It is unknown whether idarucizumab is excreted in human milk.
Fertility: There are no data on the effect of PRAXBIND on fertility.